Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 165 of 1214 results for pain

  1. Naldemedine for treating opioid-induced constipation (TA651)

    Evidence-based recommendations on naldemedine (Rizmoic) for treating opioid-induced constipation in adults who have had laxative treatment.

  2. Birch bark extract for treating epidermolysis bullosa (HST28)

    Evidence-based recommendations on birch bark extract (Filsuvez) for treating partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa in people aged 6 months and over.

  3. Pain management: chronic pancreatitis:- Is the long-term use of opioids more clinically effective and cost effective than non-opioid analgesia (including non-pharmacological analgesia) in people with chronic pain due to chronic pancreatitis?

    Recommendation ID NG104/3 Question Pain management: chronic pancreatitis:- Is the long-term use of opioids more clinically effective and

  4. Irritable bowel syndrome in adults (QS114)

    This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.

  5. Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (NG206)

    This guideline covers diagnosing and managing myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) in children, young people and adults. It aims to improve awareness and understanding about ME/CFS and when to suspect it, so that people are diagnosed earlier. It includes recommendations on diagnosis, assessment and care planning, safeguarding, access to care and managing ME/CFS and its symptoms.

  6. Burosumab for treating X-linked hypophosphataemia in adults (TA993)

    Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.

  7. Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over (HST20)

    Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.

  8. Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)

    Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease in adults.

  9. Eliglustat for treating type 1 Gaucher disease (HST5)

    Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults.

  10. Asfotase alfa for treating paediatric-onset hypophosphatasia (HST23)

    Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in babies, children, young people and adults.

  11. What are the key factors, including additional care and support, that influence participation* and quality of life in people with neuropathic pain?

    that influence participation* and quality of life in people with neuropathic pain? Any explanatory notes(if applicable) * The World...

  12. Stereotactic radiosurgery for trigeminal neuralgia (HTG608)

    Evidence-based recommendations on stereotactic radiosurgery for trigeminal neuralgia in adults. This involves focusing radiation on the trigeminal nerve to damage it, thereby relieving pain.

  13. What is the impact of drug-related adverse effects on health economics and quality of life in neuropathic pain?

    quality of life in neuropathic pain? Any explanatory notes(if applicable) Pharmacological agents for neuropathic pain are...

  14. Percutaneous vertebroplasty (HTG3)

    Evidence-based recommendations on percutaneous vertebroplasty for spinal metastases. This involves injecting a special bone cement into the spine to relieve pain and stabilise the fracture site.